Clinical Trial Update: The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19 [Phase 4]

View source ↗

Summary

Phase 4 study evaluating nintedanib for slowing lung disease in patients with fibrotic or non-fibrotic interstitial lung disease related to COVID-19 has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease
• Pulmonary Fibrosis

Drugs mentioned

• OFEV (Nintedanib)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Pulmonary Fibrosis, Interstitial Lung Disease | Phase 4 | Status: COMPLETED